Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.

BMC Cancer · 2015 · PMC4607139 · PMID 26466893

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

Once again, IHC subtypes (Luminal B/HER2-negative and, with borderline significance, triple-negative), instead of SBR grade, HER2 and HR, were independently associated with DFS (Additional file 2 : Table S2).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.